HUE032090T2 - Az activin IIB receptor stabilizált variánsai - Google Patents
Az activin IIB receptor stabilizált variánsai Download PDFInfo
- Publication number
- HUE032090T2 HUE032090T2 HUE09761055A HUE09761055A HUE032090T2 HU E032090 T2 HUE032090 T2 HU E032090T2 HU E09761055 A HUE09761055 A HU E09761055A HU E09761055 A HUE09761055 A HU E09761055A HU E032090 T2 HUE032090 T2 HU E032090T2
- Authority
- HU
- Hungary
- Prior art keywords
- seq
- polypeptide
- poz
- substitution
- ahol ahol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
Claims (5)
- ISM WLVK Η,ΗΓ.Λ ï rt MN JUSV L .JvfoláU fehérje., amely egy stabilizált aGivin ffB receptor poupepdóct tartalmaz* ahol a fc'oKm forge ροΐίρορόόίό » »oebh expound < davtn k ft fS|} orv oo HVp* d ,H«J\vvk , v<v\HUÍá,(U ιΐΊ i 12 rS - v tm 1 ' m \ S mutatjuk be fb| egy polipeplid, amely legalább 90%-os szekvencia-azonosságot mutat (a)~val, ahol a pohpeptid epv W-t vagy eg\ \ t tarínbrw,' a ? \zanm s/ckxenue 2<v,rt pozienoanak megfeleld pozícióban, és egy Tó tartalmaz a 2. számú szekvencia 44 es póznájának megfelelő pe/h.uoban. aboi a pohpeptal Kq*s ken kim <» mmartaünho . „ acte »n \ he,, vagy a GDT·· 11 -hez. és fp) polipeptldek, amelyek legalább 9$%-os s^vencm-azonosságot mutatnak la)-vul. ahol fe poUpepiid egs W-t vagy egy Yo tartalmaz a 2. számú szekvencia 28-as pozíciójának megfeleld pozícióban, és egy Tó tartalma*. :é '2, izihmoäzekycncla 44-esr pozíciójának megtetelö pozícióban, ahol a poiipeptkl képes kötődni a rmosztatmhoz, az activm Aá% vagy a GDP-1 Ghez,
- 2. Az 1. igénypont szerinti fehérje, ahol a poiipepód legalább egy heiemldg polipepüdhez mpcsolóclA:, 3. A 2. igénypont szerinti lehetje, ahol a heterológ polipeptid egy IgG Te dorne«, 4. Λ 2, igénypont szerinti fehérje, ahol a heleroiőg polipeplid egy linker szekvenciával vápádiódík a poHpepîùihez. A A 4. igénypont szerinti tehet je, ahol a linker sztkviniiÉ a 25. számú szekvencia-záz.lat, 27. számú szeks enda-\ áztat, 38, számú szekvencia-vázlat, 40, számú szék vendu-vázlat. 42, odmú szekvencia-vázlat. 44. számú szdkvencia-vázlat, 43, számú szekvencia-·vázlat, 46. számú szék-zenein-vázlat, 48, számú szekvencia-vázlat. 49, számú szekvencia-vázlat és 50. számú szekvenda-eázlat csoportban bemutatón szekvenciák közül választhatjuk ki. ú, Λ 3. igénypont szerinti lehérje, ahol a fehérje az alábbi cső port föl választó poli pepi idei .artaimaz; {a| egy polipéptid, amelynek a szekvenciáját a 8„ IC)., 16, lg 18. számú szekvencia-vázlaton mutálj ok. he ÇP) egy pohpeptid, amely legalább 90%-os szekvencia-azonosságot mutat tai-sai, ahol a pobpentu! ee\ W-t s xgv ec\ Y-t t muhmtz a 2 ,ιζ,ηη. -vedcm.; >. 28- o pvcavasuk vk o e.vtvíoo f G C', I-t tat.a n\o a * cn.i \ a i u< ' -4 5 m d megtelem pozícióban. ahol a polipeplid képes kötődni a mloszlaónhoz, az auhm A-hoz, vagy a GDI'-} t-he>\ és |c) pohpaptidek, amelyek legalább 95%-os szokvenctá^axonosságot mutatnak inyvah ahol a pohpeptid egy W-t vagy egy Y-t tartaíovaz a 2. számú szekvencia 28-as pozíciójúnak mvglmdo pozicu'han, cs ogy ló tartalmaz a 2 szama szvkveoma 44 e\ ptvnciótanak megfelelő pozícióban, ahol a pohpeptid képes kötődni a mioszfatinlmz, az acuvm A-hoz, vagy a GDf-1 iótéz. T« lóit kK t- I > V }» s',nn,i s ok vc» v »-vas’ » , \ m ' > \ *. · telked}::. B. (/obit tehene, amely egy stabilizált at. mm H B receptor poHpepùdet levAeiKuB; «a* te. car mvi .* xmKrn ;dm- pehpv l'ink.t * '- o\, κοζο - s>T'Uhvl v abs.nhaitul- ki (a) egy poltpepùd, »moly a 2. s/amû szekveneia-vádimm be rut itat ott .xsekveuciávm rendesek.. , ed V îcK'^ck kogy cm mmmvm.os k'ÈMttes \ a- e ? '-' 'eme szodooou Nb a- em love porte* zham » * net ammosmes he'venoMS v<m a ' s-verni rockseneia d es^vziemja-b&n levő pozícióban, ahol a 2$-:ts pozícióban lesd hdyeUesiUN iohe? W '»gy >, <-'* a P***' mohán bvo-heiyôfeesii^ïi.l; (b) cm pohpeptid. umd\ a 2 szmitu vek sevens s'? d-vs er' n en u oaotu » *' Kí 5 s' rendelkezik, azzal az eltéi-éssel. hogy egy aminoàavas helyettesítés ven a 2. szama szeievencta zü· as pozleléfábaü levd pozícióban, és egy aminosavas helyettesük van a 2. .számú szesvetusa 44-es ptjzkléjába« levő pozleióham ahol a 28-as pozícióban levő helyettesítem lehel. V* vagy s. es a ;»t es pozícióban tévé helyettesbe*»B ; te) egy poiipephd, amely a 2. számú szekvencia 23-134-es amlnosavat aozóttí szekvenciával mm held Ά a/< al . élteievd, bogv egs umnoema» HelyctttemK van a 2 scmAi saóo'Ko „s ss pozidojában levő poz.ieii.lbnn, és egy amínosavas helyettesítés van a 2- izávm szekvencia 44-es oozidójában levő pozícióba«, ahol a 28-as pozícióban levő helyettesítes. lehet Y*: sagy N - «s a 44. es pozícióban levő helyettesítés 1 ; hl) oe\' rxdipeptich amely a 2. számú szekvencia 25-l34-cs aminosavar közötti szekvenciával crée \o<n . z ! '? d e'OsO hoe> e„^ u V'.’s \ Kettes tes van a ** » mmu s^edenu ,, u as pozíció iában lesé pozícióban, t-s egy tamnosavas helyettesítem van a a. számú szekvencia 44-cs y,n , m V },i\ leve* puítviob m. vl ni a 28 .u ,<v , v ?h n eső hcKdtosd',» tehet V\ v,p>v v. es a tt es pozícióban levő helyettesítés T; (e) egy pokpepttvi, amely legalább üö%-o$ szekvencia azonosságot mutat az (a) Hd> lantban sze-rop Ili szekvenciák bármelyikével. azzal az eltéréssel, bogy egy aminosavas helyettesítés van a z.. számú szekvenem 2h\í< poz**.iojdun levő pozícióban, e* vgs unnnosavus hdy enemies van a 2 szama szekwmcta 44-vs pooctoinbar. kno pozícióban, ohm a 28-as pozien-okm leve helyencsíte^ Mxt \\ x.^y k.esvt t-bcv póz Klóban levő helyem.ados I
- 9. Izolált mikleiasav molekula, amely a 8. igénypont sz.eriids pokpepudet sóón In poliouklcotklot tartalmaz. W< Izolált tmklditÄ Jlólélmlá, iatbely az alábbi csoportból választható poimukleotmoi tartalmaz; (al egy folnmkleotid, amely egx olyan pob.|Xfn*k't kod n. nndym s i vobcv <* ot a 3 c 12. és !4. s/mu'i szckveneia-vazlaam rautatmkbe {h; egy pohnukkond, amely vg> nl\,ai pohivpodet koi.nl. .r .. x 'egakbb ,'s v.c.. > cla-azonosságot mutat («}-γ»Ι, ahol a polipcptld egy W-t vagy egy V-t tartalmaz a 2. o',mm s.vkxukia 2e-as onzicuíjmak pv^ndelo p»> etóban > ' I f t,r ! no <s smnm szekveneta 4a es pozK'ioyan.*é mcgicleió ptizicmlun. ahol 4 poltperod keres ko tödíh a mioaztntinboz, az aeitvm Λ-hoz, vagy a (,Η.)Ι'- ! I -nez. és tgó egs po m* klc*u»d. an c v i'p < \ η n '' dot kodé t v ,g , b'á' *\ e»n ' dmazmtosságoi mutat 4a)-val, ahol a po II pepi ki egy W-f vagy egy Y-t tartalmaz a 2. számú szekv-oiKíia 2S-as pozleimánuk mcg-'delö pozkuóhatt. és égy I -l lurtnimaz a 2. számú szekvoncH): 44 es pozíciójának mc..;ck'ló on/.ciol .m. a!>ï? a j\v*>vppd \cpcs V*-litlni p tiloaztathúioz. áz attívm Λ-hoz, \ agy a GDI -11 -bűz. 11. \ h' sœnsiii ms\ ^ * s<ï\ rt o v \ t - «u « 0 «Ν'* * uk v > d k <^n» » · kb*.etkezo csoportból \álaszthnijak ki 3 , '« Π és Π s/amu szekvencia, satumra >.ace kompomon* terei.
- 12. V ptvViîsO!-'!. f'uk'e ' ! m,s\U <· d'O! > H > tuh.^OUw.tUM« î Z C '-iegakhh egy hcteiolèg khèrik ködeié pnimukleotidot. 13. A 12. Igénypont szériáit hülddnsav mojekglàg^i'ly a kdyeilpző csoportból válaszé káté polinukleutidoi tartalmaz; iá) i.fg> polinnkieotkl. amely egy olyan poljpepíidd kódok a melynek a szeavimeimát a S,. 10.. 16. es IS. »zárná szekvencia-vázlaton mueniuk be (b) egy polinukleottd, amely ogy olyarrpolipeptidet kódol, amely legalább 903»-os s?.ekven.< ; eis-iTzcmosságot mutat (anvak ahol a pnii pepiid egy W-í vagy egy Y-t tartalmai a 2- szama szekvencia 3$~as pozíciójának megfelelő po idd óban. és egy I 4 tartalmaz a 2. s/ámu szek-'.énein 44-es pozícióiénak meg felelő pozícióban. ahol a pohpepnd képes kötődni a miosztat inhoz, az uethm A-hoz\ vagy a (.sí >}-! hheu, és (e) egy poimukieotid. amely olyan pokpepudet kódok amely legalább 95%-o* s/eievcnei;*·· azonosságot mutat tuovak ahol a pofipeptid egy kV-i vagy «,g> V-t íaouinu, a , s/amú sielyenck pozíciójának megfelelő pozfdóban} és egy T-i tartalmaz a 2. ázáson szék-vendit 44-es pozíciójának megfelelő pozícióban, ahol a pofi pepiid képes kötődni a mmszUimhoz, az min m Vlm., \ag% a U1 >1 11 -hoz 14.. A 13 igénypont széttnlt ηοΜίπηνο mokkáin, ahol a pohnukleoud a'chsenciakti a következő csoportból vakíthatná, k'r Ύ, e., 15. (s 17. azàmù uckvenun, vagy ezek komplems. morei 15. Λ 10. Igénypont szerinti nukkinsav molekula, ahol a poliratkleotid működés szem* smt aKö ο V n vi sd »,\.to ην> ,κ íu v soze o.voti * d'oz kap», v.od \ lő. Egy rekomhináns vektor, amely a 10. igé«>fx>nt szerinti nukieinsav tsoÄpitisrtgii soazm 1?. Gazda ou ,mv s , ' e< n.enyp> r n< c*mu mkombma’'« 'ektort tat ta- rezz. Ifi. A Π. igénypont szerinti gazdasejt. ahol aga/.dasek egy emlős smi. !t. 1 Paras cgv u Y tRlÜ'l feherp e uaUítavira aaz.k jellemezte. bo.„> a " yem,p<au. -,,ν I dm< ne* uho > ,\orx> ok ΚΝζο,> lu*'os/uù, eme,·' um 0¾ nyék ok -os. ok . lobéi c represszióját, majd kinyerjük a tehénét.
- 20. Gyógyászati készítménye amely hatásos mennyiséget tartalmaz az l-b igénypontoké unj' \>o tnt dtcieho \ np s m^. uv *·& v he n>' μ ~ ! 21. Λ 2u igeuypontv t m kevouvíg t ki.máz,«,* gyógyvérként 22. \ 2d. igéin pont wn no fc*u mevm izoms*a\.uVi' \ags .remhobkns rendéi lenesség kezelési eljárásában, amely amdelienesség leltet eulorbeteaseg, elldzás, biperglikómia ésrcsoníve.SE> lés. egy iben kezelésié O"^rtdá al -.n> un. 23.. /\ 22, igénypont szerinti készítmény alkalntazása, ahol az í/omsorvadás izomsorvadá-vos Utegseg ktásetkeznienye, amehet a következők közül választhatunk Li l/omsorvadas, amiouóílás laterális szklerózís. pangásos obstmktív tüdőbetegség, krónikus szívelégtelenség, rákos ksobezia, AIDS, veseelégteíenség, uréniiat reumás arthritis, életkorhoz kötődő szarkopénia, szervser' yadáh egrplts akgói szkdrámíh androgén megfosztás, égési sérülés, cukorbetegség, igomsurvadási bosszú ideig tartó ágyny-ugalom miatt, gerincvelő sérülés, s/o<>k. csonttörés, életkot vagy expozíció mi kro-grav i táci óva 1. 24. Λ 20, igénypont sz.erimi kéa/itnjény alkalmazása egy betegség kezelésében, amelyben ?iz neuem title v »> "sza 'd \ eu 'u ^ " 1 dr f.n ó.-r de\- -, ' z 2S. A »pompát \oo*'»»i xeU«« ? *»n***txAxiS'* xaox nkiatvhhu" »O'KJollorC' Og - âîimiy lohst CiiköTbofcgség, elMeás, Mjp^rgiiMim.m ososisisiyeaztës - vagy rák: teoMsérs szolgáik e!|é-sásban valé alkalmazássá: ahol az aeilsm iúlskpreAzIlödsk agy llyta kezelésre szerűié alanybásy ahol a vektor képes; egy syáctRÜB ptigepbcl expsxvsziéját szabályozós az aiaoybam lő, A készítmény 24. igénypont ..szerinti alkalnsazása, vagy a vektor "25 < igértypotri szeri sn ti: alkalnspaása^ahol a rák petefészek fák '2% M%: lAk igétsypppfek bármelyike szerinti lelökje alfealsóazása egy eyitáskasg uielynek ásljtt a zssmtetttes izotsigkuég: Mlvelése, vagy a zstrilMsitel szotllömeg zlirtblrieglieZ visaoíiyitptt ara-gyáuakrs giveliaSj ahol az elíáráy p&mm ·· #%Ht· ieél: kie^î<ssl eljárása iemplàvak
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20025008P | 2008-11-26 | 2008-11-26 | |
US25906009P | 2009-11-06 | 2009-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE032090T2 true HUE032090T2 (hu) | 2017-09-28 |
Family
ID=41693455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09761055A HUE032090T2 (hu) | 2008-11-26 | 2009-11-24 | Az activin IIB receptor stabilizált variánsai |
Country Status (38)
Country | Link |
---|---|
US (5) | US8410043B2 (hu) |
EP (2) | EP2370463B1 (hu) |
JP (3) | JP5611222B2 (hu) |
KR (3) | KR20170105124A (hu) |
CN (2) | CN102245634B (hu) |
AR (1) | AR074397A1 (hu) |
AU (1) | AU2009320364B2 (hu) |
BR (1) | BRPI0920962A2 (hu) |
CA (2) | CA2743850C (hu) |
CL (1) | CL2011001239A1 (hu) |
CO (1) | CO6382163A2 (hu) |
CR (2) | CR20160443A (hu) |
CY (1) | CY1118754T1 (hu) |
DK (1) | DK2370463T3 (hu) |
EA (2) | EA201100832A1 (hu) |
ES (1) | ES2600491T3 (hu) |
HK (1) | HK1162545A1 (hu) |
HR (1) | HRP20161450T1 (hu) |
HU (1) | HUE032090T2 (hu) |
IL (2) | IL212773A (hu) |
LT (1) | LT2370463T (hu) |
MA (1) | MA32936B1 (hu) |
ME (1) | ME02652B (hu) |
MX (1) | MX2011005505A (hu) |
MY (1) | MY159483A (hu) |
NZ (2) | NZ604818A (hu) |
PE (2) | PE20120206A1 (hu) |
PL (1) | PL2370463T3 (hu) |
PT (1) | PT2370463T (hu) |
RS (1) | RS55369B1 (hu) |
SG (2) | SG171813A1 (hu) |
SI (1) | SI2370463T1 (hu) |
SM (1) | SMT201600417B (hu) |
TN (1) | TN2011000238A1 (hu) |
TW (1) | TWI486166B (hu) |
UA (1) | UA107921C2 (hu) |
WO (1) | WO2010062383A2 (hu) |
ZA (1) | ZA201104648B (hu) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
EP1973559B1 (en) | 2005-11-23 | 2013-01-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
RU2473362C2 (ru) | 2007-02-01 | 2013-01-27 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EP2120999B1 (en) | 2007-02-09 | 2012-08-29 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
WO2009038745A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
DK3494986T3 (da) | 2008-08-14 | 2020-08-03 | Acceleron Pharma Inc | GDF fanger |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
NZ604818A (en) | 2008-11-26 | 2014-07-25 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
EP3805259A1 (en) | 2009-06-12 | 2021-04-14 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
WO2012006293A1 (en) * | 2010-07-06 | 2012-01-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
SG10201506405YA (en) | 2010-08-16 | 2015-10-29 | Amgen Inc | Polypeptides That Bind Myostatin, Compositions And Methods |
WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
KR20140108562A (ko) * | 2011-12-19 | 2014-09-11 | 암젠 인코퍼레이티드 | 변이체 액티빈 수용체 폴리펩티드 단독 또는 화학 치료법과의 결합, 및 그들의 용도 |
CN104540961A (zh) | 2012-06-11 | 2015-04-22 | 安姆根公司 | 双重受体拮抗性抗原结合蛋白及其用途 |
NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
SG10201706148WA (en) * | 2013-02-01 | 2017-08-30 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
US20140220033A1 (en) * | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
CN104693270B (zh) * | 2013-12-10 | 2018-10-16 | 清华大学 | 一种用于融合蛋白的连接肽 |
WO2015108972A1 (en) * | 2014-01-14 | 2015-07-23 | Santa Maria Biotherapeutics, Inc. | Activin inhibitor response prediction and uses for treatment |
KR20170035891A (ko) * | 2014-06-13 | 2017-03-31 | 산타 마리아 바이오테라퓨틱스, 인코포레이티드 | 제형화된 수용체 폴리펩타이드 및 관련 방법 |
MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
KR20170141215A (ko) * | 2015-04-06 | 2017-12-22 | 악셀레론 파마 인코포레이티드 | 싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도 |
KR20180002661A (ko) | 2015-04-06 | 2018-01-08 | 악셀레론 파마 인코포레이티드 | ALK7:ActRIIB 이형다합체와 이의 용도 |
SG10201913747PA (en) | 2015-04-22 | 2020-03-30 | Biogen Ma Inc | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
JP6987072B2 (ja) | 2016-03-10 | 2021-12-22 | アクセレロン ファーマ インコーポレーテッド | アクチビン2型受容体結合タンパク質及びその使用 |
KR20190075078A (ko) | 2016-10-05 | 2019-06-28 | 악셀레론 파마 인코포레이티드 | ALK4:ActRIIB 이형다량체 및 이의 용도 |
EP3538128A4 (en) | 2016-11-10 | 2020-07-22 | Keros Therapeutics, Inc. | ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE |
AU2018364668B2 (en) | 2017-11-09 | 2024-05-30 | Keros Therapeutics, Inc. | Activin receptor type lla variants and methods of use thereof |
CN112292144A (zh) | 2018-01-12 | 2021-01-29 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
CN109320597B (zh) * | 2018-10-26 | 2021-10-26 | 中国农业科学院特产研究所 | 狐亚科激活素a蛋白及其制备与应用 |
WO2023108137A1 (en) | 2021-12-10 | 2023-06-15 | Biogen Ma Inc. | Modified actriib proteins and methods of use thereof |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
WO1994021681A1 (en) | 1993-03-19 | 1994-09-29 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
DE69535641D1 (de) | 1994-04-29 | 2007-12-27 | Curis Inc | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ATE362534T2 (de) | 1998-11-13 | 2007-06-15 | Immunex Corp | Menschliche tslp nukleinsäuren und polypeptide |
CA2359242C (en) | 1999-01-21 | 2009-12-08 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
PL383616A1 (pl) | 2002-12-20 | 2008-04-14 | Amgen Inc. | Środki wiążące inhibitujące miostatynę |
CN1829532A (zh) | 2003-06-02 | 2006-09-06 | 惠氏公司 | 肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途 |
PT2239273E (pt) | 2003-11-13 | 2013-12-10 | Hanmi Science Co Ltd | Uma composição farmacêutica que compreende um fragmento fc de imunoglobulina como um portador |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
JP2008509927A (ja) | 2004-08-12 | 2008-04-03 | ワイス | Gdf−8阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法 |
DK1797127T3 (en) | 2004-09-24 | 2017-10-02 | Amgen Inc | Modified Fc molecules |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
DOP2006000195A (es) | 2005-09-07 | 2017-08-15 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
MX2008011232A (es) * | 2006-03-02 | 2008-09-11 | Ishihara Sangyo Kaisha | Composicion herbicida solida. |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
PL2468290T3 (pl) | 2006-12-18 | 2015-08-31 | Acceleron Pharma Inc | Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości |
TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
US8501678B2 (en) * | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TW201718635A (zh) * | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
ES2449753T3 (es) | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
WO2009038745A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
US20090226441A1 (en) | 2007-11-09 | 2009-09-10 | Minhong Yan | Activin receptor-like kinase-1 compositions and methods of use |
KR20220002710A (ko) | 2008-06-26 | 2022-01-06 | 악셀레론 파마 인코포레이티드 | 액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
DK3494986T3 (da) | 2008-08-14 | 2020-08-03 | Acceleron Pharma Inc | GDF fanger |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
NZ604818A (en) | 2008-11-26 | 2014-07-25 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
MX2011013172A (es) | 2009-06-08 | 2012-04-02 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
WO2011085165A2 (en) | 2010-01-08 | 2011-07-14 | The Brigham And Women's Hospital, Inc. | Ca-125 immune complexes as biomarkers of ovarian cancer |
MX2011011596A (es) | 2010-03-31 | 2012-02-01 | Keryx Biopharmaceuticals Inc | Perifosina y capecitabina como un tratamiento combinado para cancer. |
WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
EP2802308A1 (en) | 2012-01-13 | 2014-11-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2009
- 2009-11-24 NZ NZ604818A patent/NZ604818A/en not_active IP Right Cessation
- 2009-11-24 HU HUE09761055A patent/HUE032090T2/hu unknown
- 2009-11-24 AR ARP090104527A patent/AR074397A1/es not_active Application Discontinuation
- 2009-11-24 CN CN200980147945.3A patent/CN102245634B/zh not_active Expired - Fee Related
- 2009-11-24 EP EP09761055.4A patent/EP2370463B1/en active Active
- 2009-11-24 EA EA201100832A patent/EA201100832A1/ru unknown
- 2009-11-24 KR KR1020177025044A patent/KR20170105124A/ko active IP Right Grant
- 2009-11-24 CR CR20160443A patent/CR20160443A/es unknown
- 2009-11-24 MY MYPI2011002346A patent/MY159483A/en unknown
- 2009-11-24 DK DK09761055.4T patent/DK2370463T3/en active
- 2009-11-24 SI SI200931546A patent/SI2370463T1/sl unknown
- 2009-11-24 CA CA2743850A patent/CA2743850C/en not_active Expired - Fee Related
- 2009-11-24 KR KR1020117014720A patent/KR101720143B1/ko active IP Right Grant
- 2009-11-24 LT LTEP09761055.4T patent/LT2370463T/lt unknown
- 2009-11-24 JP JP2011538599A patent/JP5611222B2/ja not_active Expired - Fee Related
- 2009-11-24 RS RS20160909A patent/RS55369B1/sr unknown
- 2009-11-24 PE PE2011001077A patent/PE20120206A1/es not_active Application Discontinuation
- 2009-11-24 MA MA33960A patent/MA32936B1/fr unknown
- 2009-11-24 ES ES09761055.4T patent/ES2600491T3/es active Active
- 2009-11-24 CN CN201410462932.8A patent/CN104371024A/zh active Pending
- 2009-11-24 PT PT97610554T patent/PT2370463T/pt unknown
- 2009-11-24 ME MEP-2016-243A patent/ME02652B/me unknown
- 2009-11-24 MX MX2011005505A patent/MX2011005505A/es active IP Right Grant
- 2009-11-24 KR KR1020177007651A patent/KR101778134B1/ko active IP Right Grant
- 2009-11-24 PE PE2015000401A patent/PE20150680A1/es not_active Application Discontinuation
- 2009-11-24 NZ NZ627111A patent/NZ627111A/en not_active IP Right Cessation
- 2009-11-24 BR BRPI0920962A patent/BRPI0920962A2/pt not_active IP Right Cessation
- 2009-11-24 EA EA201791940A patent/EA201791940A3/ru unknown
- 2009-11-24 EP EP16179980.4A patent/EP3101029B1/en active Active
- 2009-11-24 UA UAA201107872A patent/UA107921C2/ru unknown
- 2009-11-24 WO PCT/US2009/006252 patent/WO2010062383A2/en active Application Filing
- 2009-11-24 AU AU2009320364A patent/AU2009320364B2/en not_active Ceased
- 2009-11-24 SG SG2011037777A patent/SG171813A1/en unknown
- 2009-11-24 CA CA2997971A patent/CA2997971A1/en not_active Abandoned
- 2009-11-24 PL PL09761055T patent/PL2370463T3/pl unknown
- 2009-11-24 SG SG10201703067QA patent/SG10201703067QA/en unknown
- 2009-11-25 US US12/626,375 patent/US8410043B2/en active Active
- 2009-11-26 TW TW098140431A patent/TWI486166B/zh not_active IP Right Cessation
-
2011
- 2011-05-08 IL IL212773A patent/IL212773A/en not_active IP Right Cessation
- 2011-05-12 TN TN2011000238A patent/TN2011000238A1/fr unknown
- 2011-05-26 CL CL2011001239A patent/CL2011001239A1/es unknown
- 2011-06-23 CO CO11079058A patent/CO6382163A2/es not_active Application Discontinuation
- 2011-06-23 ZA ZA2011/04648A patent/ZA201104648B/en unknown
- 2011-06-24 CR CR20110364A patent/CR20110364A/es unknown
-
2012
- 2012-04-02 HK HK12103250.5A patent/HK1162545A1/zh not_active IP Right Cessation
-
2013
- 2013-02-25 US US13/775,756 patent/US9273114B2/en active Active
-
2014
- 2014-09-02 JP JP2014177598A patent/JP5969557B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-22 US US15/004,375 patent/US10308704B2/en active Active
- 2016-07-07 JP JP2016134684A patent/JP2016199577A/ja not_active Ceased
- 2016-09-29 IL IL248128A patent/IL248128A0/en unknown
- 2016-11-03 HR HRP20161450TT patent/HRP20161450T1/hr unknown
- 2016-11-16 SM SM201600417T patent/SMT201600417B/it unknown
- 2016-11-16 CY CY20161101175T patent/CY1118754T1/el unknown
-
2019
- 2019-04-18 US US16/388,561 patent/US11685770B2/en active Active
-
2023
- 2023-06-07 US US18/206,963 patent/US20230295267A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230295267A1 (en) | Stabilized receptor polypeptides and uses thereof | |
US9284364B2 (en) | Isolated nucleic acid molecule encoding a fusion protein comprising an activin receptor | |
EP2132314B1 (en) | Variant activin receptor polypeptides and uses thereof | |
AU2016210719B2 (en) | Variants of activin IIB receptor polypeptides and uses thereof | |
AU2014210609B2 (en) | Novel activin receptor and uses thereof | |
AU2016238960A1 (en) | Novel activin receptor and uses thereof | |
MX2008005638A (en) | Novel activin receptor and uses thereof |